Swiss well being care firm Roche on Monday introduced it will purchase Telavant Holdings in a $7.1 billion transaction.

Telavant produces medication for individuals affected by inflammatory and fibrotic ailments and is within the strategy of growing a “promising new remedy” for sufferers with Crohn’s illness, Roche stated in a press launch.

The phrases of the acquisition embrace a near-term milestone cost of $150 million.

As soon as given full rights to the RVT-3101 drug — a remedy below improvement for inflammatory bowel illness, together with ulcerative colitis and Crohn’s illness — Roche goals to start out world Section 3 trials, which might contain scientific testing on a whole lot to hundreds of sufferers with the goal ailings.

“We strongly consider this novel TL1A directed antibody has the transformational potential to make a big distinction for sufferers residing with inflammatory bowel illness and doubtlessly different ailments,” Roche Group CEO Thomas Schinecker stated in a press release.

“We’re excited so as to add this promising new remedy in improvement to our portfolio and to make it obtainable to sufferers as rapidly as attainable.”

Telavant is at present owned by Pfizer and Roivant Sciences.

Within the Monday announcement, Roche additionally stated it will get hold of an choice to collaborate with Pfizer on a brand new inflammatory bowel illness drug.

This can be a breaking information story, please test again later for extra.